Compared to a great deal of thrilling evidence on association of metformin treatment with risk of pancreatic cancer, the relationship between GLP-1 receptor agonists and pancreatic cancer risk is still controversial. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.